A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium

A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium

Background & Aims: Targeting the gut–liver axis is a promising strategy for treating liver diseases. We aimed to assess the therapeutic efficacy of targeting the gut microbiota-bile acid (BA) axis using ursodeoxycholic acid (UDCA) combined with the probiotic Bifidobacterium to treat chronic...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhen Xun, Xiaobao Yao, Caorui Lin, Xinyao Yang, Yanfang Zhang, Xin Yang, Yujue He, Renquan Jiang, Yanping Lan, Yuchen Ye, Detai Ye, Shanjian Chen, Ke Ma, Wennan Wu, Siyi Xu, Bin Yang, Can Liu, Jing Chen, Qi Zheng, Qishui Ou
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JHEP Reports
Subjects:
Chronic hepatitis B
Gut microbiota
Bile acid
Immune cells
Treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S258955592500134X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items